MAR 2 9 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/501,566

Filed:

7/15/2004

1st Inventor:

UNO, Yumiko

For:

Novel Proteins and DNAs Thereof

Atty. Dkt. No.

3015 US0P

Art Unit:

tba

Examiner:

tba

Allowed:

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 524903879 US

DATE IN:

March 29, 2005

Itemized Papers/Items:

- 1. This Postcard and Certificate of Express Mailing (2 pages)
- 2. Transmittal Form (1 page X 2)
- 3. Response to Notice of Missing Requirements (1 page), submission of substitute IBM PC/AT format disk containing the CRF of the Sequence Listing, and copy of Notification to Comply with Sequence Listing Requirements (2 pages).

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP SEQUENCE Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

on this date, March 29, 2005

Dated: 3/29/05

Gail L. Winokur

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road

Lincolnshire, IL 60069 USA

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE he Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Application Number 10/501.566 Filing Date TRANSMITTAL 7/15/2004 First Named Inventor **FORM** UNO, Yumiko Art Unit tba Examiner Name tba (to be used for all correspondence after initial filing) Attorney Docket Number 3015 US0P Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Próprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Return Postcard: Request for Refund Express Abandonment Request Certificate of Express Mailing; Substitute IBM PC/AT format disk; CD, Number of CD(s) Information Disclosure Statement Copy of Notification to Comply Landscape Table on CD Certified Copy of Priority Remarks Document(s) The Commissioner is hereby authorized to charge any additional fees which may be required, Reply to Missing Parts/ or credit any overpayment to Deposit Account 500799. Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Takeda Pharmaceu Signature Printed name Mark Chao Date Reg. No. 37,293 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail # EV 524903879 US

Gail L. Winokur

Typed or printed name

IN THE UNITED STATES PATENTAND TRADEMARK OFFICE

Application No.:

10/501,566

Filed:

7/15/04

1st Inventor:

UNO, Yumiko

For:

Novel Proteins and DNAs Thereof

Atty. Dkt. No.

3015 US0P

Art Unit:

tba

Examiner:

: tba

Allowed:

Batch:

Paper No.:

Response to Notice to Comply with Sequence Listing Requirements

MAIL STOP SEQUENCE

Commissioner for Patents P.O. Box 1450 Arlington, VA 22313-1450

Sir:

In response to the Notice to Comply with Sequence Listing Requirements mailed February 9, 2005, a copy of the Notice is enclosed.

Applicants respectfully submit another 3.5" IBM PC/AT computer disk containing the CRF file in DOS Text format named 3015US0P SEQ.TXT.

The Sequence listing CRF contains the same information as the written sequence listing as originally filed. Further updating of the US Patent Application identifying serial number, filing date and inventor names of the file has been done. The CRF Sequence Listing contains no new matter.

Respectfully submitted

Dated: March 29, 2005

(847)383-3372 (847)383-3391 1/6/1

Mark Chao, Ph.D., Reg. No. 37,293 Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA



Date Mailed: 02/09/2005

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.unpto.gov

ATTY. DOCKET NO. U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT 3015 USOP Yumiko Uno 10/501,566 INTERNATIONAL APPLICATION NO. PCT/JP03/00311 23115 I.A. FILING DATE PRIORITY DATE TAKEDA PHARMACEUTICALS NORTH AMERICA, INC INTELLECTUAL PROPERTY DEPARTMEN 01/16/2003 01/18/2002 **475 HALF DAY ROAD** SUITE 500 **CONFIRMATION NO. 8263** LINCOLNSHIRE, IL 60069 **371 FORMALITIES LETTER** 1 5 2005 OC000000015073078* LP OFPT

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

INDIA L EVANS

Telephone: (703) 308-9140 EXT 212

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO. INTERNATIONAL APPLICATION NO. ATTY. DOCKET NO. 10/501,566 PCT/JP03/00311 3015 USOP

FORM PCT/DO/EO/922 (371 Formalities Notice)